PROLOR Biotech Inc. (PBTH) Cleared by FDA for US Phase II HGH Trials

QualityStocks would like to highlight PROLOR Biotech Inc. (NYSE AMEX: PBTH), a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, biobetter, proprietary versions of already-approved therapeutic proteins, that currently generate billions of dollars in annual global sales.

In the company’s news yesterday,

PROLOR reported receiving FDA regulatory clearance for Phase II clinical trials of hGH-CTP, the Company’s improved and longer-acting human growth hormone.

The CTP technology allows PBTH to isolate short, naturally occurring amino acid sequences and develop them into cheaper, safer, easier to implement and more effective human growth hormones.

FDA approval follows fast on the heels of PBTH’s submission of an investigational new drug application for hGH-CTP, which contained extensive preclinical and Phase I data, in addition to proposed pre-Phase III animal study projections.

With an hGH-CTP Phase II clinical program already underway in Europe, PBTH has quickly built up a strong profile for what promises to be a superior version of human growth hormone.

CEO of PBTH, Dr. Abraham Havron, called FDA approval for Phase II trials in the US a major milestone for the Company, characterizing Phase II trials as an integral part of a sophisticated and coordinated development program designed to yield marketing authorization in US, European and global markets.

The Company will utilize European infrastructure for generating the data and, as Mr. Havron points out, FDA clearance helps to ensure synchronization with target markets, yielding a much larger commercialization window, even though trial sites may not be located in the US.

Growth hormone therapy currently requires multiple injections per week, which can be a sort of “living nightmare” for patients. The PBTH product, hGH-CTP, allows patients to live their lives more freely, requiring only two to four injections in an entire month.

The Phase I trials met all safety and tolerability endpoints, and Phase II will be constructed to further validate the safety/tolerability as a randomized, open-label, dose-finding structure which will also evaluate hGH-CTP’s pharmacokinetic and pharmacodynamic properties. That is, while the pharmacokenesis portion mathematically models drug concentration rates in bodily fluids, the pharmacodynamic portion will study the course of drug administration over time relative to the intensity of the effects.

Over 14 sites in Europe will play host to validating the promising aspects of what developers expect to be an extremely powerful revenue engine.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.